Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Pandoraon Dec 03, 2022 2:18am
235 Views
Post# 35148295

RE:RE:Pumping and Dumping

RE:RE:Pumping and Dumping
Yoly900 wrote: It's a scam way penny stocks raise money with air. Why are we in the Pennie's THINKKKKK TESTING SITES ALL DOCTORS SCIENTISTS WHY ARENT THEY BUYING? Whyyyyy where. What happened to cannabis   Cannaboid J V OH COVID NEXT YEAR 2024 how isn't this scsmmmm


The Cannabinoid thing as you call it is still on the back and forth routine with the U.S. patent office.

In August 2022 the Company submitted an Amendment & Arguments regarding a non-final rejection by the USPTO.

On October 25, 2022 the documents were returned to the Company by the Examiner who issued another non-final rejection based on things he did not like in the amendment & arguments. So the ball is back in the Company's court to respond to whatever the Examiner was not happy with. Each of these back & forth's is normally given 90 days. That would suggest the Company has until about the end of January to run it back for another review -- or to possibly abandon it depending on what the Examiner's concerns were. Roger Dumoulin-White and Arkady Mandel are listed as the "Inventors" so presumably it is they that are rewriting a new amendment.

16/365,148 | T1081/20069:

METHOD FOR TREATING CONDITIONS ASSOCIATED WITH HYPERPROLIFERATING CELLS COMPRISING COMBINED ADMINISTRATION OF A CANNABINOID RECEPTOR AGONIST AND RADIATION THERAPY

Application #

16/365,148

Attorney Docket #

T1081/20069

Patent #

 

Status

Non Final Action Mailed - 10/21/2022

Filing or 371 (c) date

03/26/2019

Documents & transaction history

 
10/25/2022 CTNF Non-Final Rejection 24 Preview DOCX / PDF / PNG / XML
10/25/2022 SRFW Search information including classification, databases and other search related notes 2 Preview PDF
10/25/2022 SRNT Examiner's search strategy and results 3 Preview PDF
08/24/2022 SA.. Supplemental Response or Supplemental Amendment 1 Preview PDF
08/24/2022 CLM Claims 3 Preview PDF / XML
08/24/2022 REM Applicant Arguments/Remarks Made in an Amendment 3 Preview PDF / XML
08/24/2022 REM Applicant Arguments/Remarks Made in an Amendment 9 Preview PDF / XML
08/24/2022 WFEE Fee Worksheet (SB06) 2 Preview PDF

Utility
KARA RENITA MCMILLIAN
1627
514/185.000
Yes
Small
09/26/2019
-
4146
-
-

Correspondence address

3000 - CAESAR RIVISE, PC
 
7 Penn Center, 12th Floor
1635 Market Street
PhiladelphiaPA
UNITED STATES

Inventors

  • Roger DUMOULIN-WHITE
    Toronto (CA)
  • Arkady MANDEL
    North York (CA)
  •  

Applicants

  • Theralase Technologies, Inc.
    Toronto (CA)

  •  

<< Previous
Bullboard Posts
Next >>